AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and with PREMIA Holdings (HK) Ltd.
Breaking News! ROS1, EGFR included on health insurance list of SK, TW
Breaking News! South Korea Includes AmoyDx® ROS1 Kit on National Health Insurance List Taiwan, China Includes AmoyDx® EGFR Kit on Health Insurance List
Visit AmoyDx at AMP Global Congress 2019 in Hong Kong
AmoyDx will be exhibiting at AMP Global 2019 in Hong Kong from 16 May to 18 May. Mark your calendar and visit us at Booth 34#, AsiaWorld-Expo – Hall 2. See you in Hong Kong.
Visit AmoyDx at European Lung Cancer Congress 2019 in Geneva
AmoyDx will be exhibiting at European Lung Cancer Congress 2019 (ELCC 2019) from 10 Apr to 13 Apr. Welcome to visit us at Booth 21. See you in Geneva, Switzerland.
Visit AmoyDx at AACR Annual Meeting 2019 in Atlanta, USA
AmoyDx will be exhibiting at AACR Annual Meeting 2019 in Atlanta, Georgia, USA. Welcome to visit us and say hello at Booth 4260. See you there.
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit was approved by Chinese National Medical Products Administration (NMPA) on February 27, 2019, intended for qualitative detection of gene BRCA1 and BRCA2 mutation in patients with different cancer types